Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25825650 | 0.93 | GLP1R (0.51) | GLP1RTLR2NOD1SIRT2ALB | |
| SCHEMBL13753618 | 0.93 | GLP1R (0.51) | GLP1RTLR2NOD1SIRT2ALB | |
| SCHEMBL45887 | 0.84 | GLP1R (0.57) | GLP1RTLR2NOD1SIRT2ALB | |
| SCHEMBL16525843 | 0.82 | GLP1R (0.56) | GLP1RTLR2NOD1SIRT2ALB | |
| SCHEMBL45885 | 0.82 | GLP1R (0.56) | GLP1RTLR2NOD1SIRT2ALB | |
| SCHEMBL24589082 | 0.81 | GLP1R (0.61) | GLP1RTLR2SIRT2FOLH1LPAR3 | |
| SCHEMBL27400825 | 0.81 | GLP1R (0.45) | GLP1RTLR2SIRT2 | |
| SCHEMBL25919998 | 0.80 | GLP1R (0.47) | GLP1RTLR2NOD1SIRT2ALB | |
| SCHEMBL24601556 | 0.80 | GLP1R (0.52) | GLP1RTLR2NOD1SIRT2ALB | |
| SCHEMBL12892953 | 0.79 | ROCK2 (0.44) | GLP1RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | DNPEP, PAM, ASNS | GLP1R 472/4885TLR2 2413/4885NOD1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.